title: Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
abstract: OBJECTIVE
  To evaluate and compare positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance imaging (wbMRI) in the correct staging of patients with advanced nonsmall cell lung cancer (NSCLC).
  
  
  METHODS
  Fifty-two patients with an NSCLC stage IIIa or IIIb (36 males and 16 females) were included in this study. Patients were referred to our department for restaging. Within 1 week PET/CT and wbMRI were performed in all patients. Images were examined independently by 2 experienced physicians from the Department of Nuclear Medicine and Radiology. Afterward, consensus reading was performed. In 22 patients, surgery served as gold standard, whereas in 30 patients, follow-up controls (after 2 months) were performed.
  
  
  RESULTS
  The use of wbMRI correctly T-staged all patients. Especially volume interpolated breathhold examination sequence correctly T-staged all tumors. PET/CT did not correctly stage chest wall infiltration in 4 cases [sensitivity 92.3% (P < 0.05 to wbMRI)/specificity 100%], verified by surgery. PET/CT correctly N-staged 51 patients (sensitivity 96.1%/specificity 100%). WbMRI showed a significant tendency to understage N-status [sensitivity 88.5% (P < 0.05)/specificity 96.1%]. Different N-status by PET/CT changed operability in 4 patients. In 2 patients, distant metastases were detected by both techniques.
  
  
  CONCLUSIONS
  In the correct staging of advanced NSCLC, PET/CT has advantages in N-staging. This is of high relevance for therapy planning. WbMRI especially using volume interpolated breathhold examination sequences, has certain advantages in T-staging.
authors.affiliation: Department of Radiology, University of Tuebingen, Tuebingen, Germany. christian.plathow@uniklinik-freiburg.de
authors.forename: Christian
authors.initials: C
authors.lastname: Plathow
authors.forename: Philip
authors.initials: P
authors.lastname: Aschoff
authors.forename: Mathias Philip
authors.initials: MP
authors.lastname: Lichy
authors.forename: Susanne
authors.initials: S
authors.lastname: Eschmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Hehr
authors.forename: Ingo
authors.initials: I
authors.lastname: Brink
authors.forename: Claus D
authors.initials: CD
authors.lastname: Claussen
authors.forename: Christina
authors.initials: C
authors.lastname: Pfannenberg
authors.forename: Heinz-Peter
authors.initials: HP
authors.lastname: Schlemmer
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000601:surgery; D003287:Contrast Media / Q000008:administration & dosage; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007472:Iohexol / Q000031:analogs & derivatives; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015588:Observer Variation; D049268:Positron-Emission Tomography / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*; D051598:Whole Body Imaging / Q000379:methods*
chemical_list: D003287:Contrast Media; D019788:Fluorodeoxyglucose F18; D007472:Iohexol; C038192:iopromide